Stray Dog
EN中文
EN中文

Prices are Hyperliquid perpetual futures: contracts that track each stock and trade 24/7. They are not exchange prices and can differ from them, most of all while US markets are closed. Change is over 24 hours. For information only.

  • TSLA—
  • PLTR—
  • HIMS—
  • SPCX—
  • SOFI—
  • BTC—
…Loading prices
HIMS

Employers cutting GLP-1 benefits in 2027 is a structural tailwind, and HIMS leads Novo's channel on volume

Sources (7)

A new medium-term structural tailwind: among employers that cover GLP-1s, 10% plan to drop the benefit in 2027. Employer insurance is the largest source of health cover in the US, with more than 150 million people enrolled (Business Group on Health survey;

Read more

soaring Wegovy and Zepbound costs are the direct trigger, and Cigna has already stopped covering them for its own staff). Users who lose employer reimbursement are pushed towards DTC cash-pay platforms, which is exactly HIMS's subscription model. That turns the headwind of insurers cutting off GLP-1s into a tailwind from a bigger cash-pay pool. On top of this, Jamey Millar, Novo's EVP of US operations, said plainly that since the partnership began in March, HIMS has driven the most volume of all Novo's telehealth partners. That confirms HIMS leads in executing Novo's branded-drug channel. But employers dropping cover is a gradual trend that only lands in 2027, not an immediate catalyst, and a 10% drop does not mean all of those users go to HIMS (NovoCare and LillyDirect, from $149 a month, and TrumpRx are also chasing the cash-pay pie). The valuation is stretched: the shares are up about 36% in June, and the current $32.70 is above most sell-side targets (consensus $28-29). The real binary event is still the FDA peptide advisory meeting on 23-24 Jul. In one sentence: fundamentals have a new medium-term tailwind, but the price has already run ahead on sentiment, and the risk/reward has not improved.

Key evidence

  • Analysis by Reuters and The Independent on 25 Jun: employer insurance is the largest source of health cover in the US (more than 150 million people enrolled). In 2025 about 43% of employers covered GLP-1s for weight loss, and the figure is expected to be flat in 2026.
  • Survey by Business Group on Health (a policy research body for large employers): 10% of employers that now cover GLP-1s plan to drop the benefit in 2027, with soaring Wegovy and Zepbound costs the direct trigger. Cigna has already stopped coverage for its own employees.
  • Jamey Millar, Novo's EVP of US operations, said plainly that since the partnership began in March, HIMS has driven the most volume of all Novo's telehealth partners. That confirms HIMS leads in executing Novo's branded-drug channel.
  • Sell-side reaction: 7 analysts have raised their 2026 estimates since May, partly because of the Novo partnership. Consensus revenue is now about $2.89 billion for 2026 and about $3.45 billion for 2027.
  • Raul Shah of DocShah (position under 1%): weight loss is currently about 1/3 of total revenue, and he expects that share to keep rising with the GLP-1 craze. The US weight-loss market is shifting from reliance on insurance to self-pay.
  • On 25 Jun TipRanks attributed the pullback to regulatory worries and technical selling after the shares broke below long-term moving averages (technicals and sentiment, not a new deterioration in fundamentals)
  • Closed Wednesday at $32.70, up about 36% in June and above most sell-side targets (consensus about $28-29)

Catalysts to watch

  • FDA peptide advisory meeting on 23-24 Jul: the real binary event
  • Employers gradually dropping cover from 2027, expanding the DTC cash-pay pool
  • Continued confirmation of volume through Novo's branded-drug channel (HIMS already confirmed as the top seller among Novo's telehealth partners)
  • More sell-side upgrades to 2026 and 2027 estimates (7 analysts since May)

Risks

  • Employers dropping cover is a gradual trend that only lands in 2027, not an immediate catalyst
  • A 10% drop in cover does not mean all of those users go to HIMS. Novo's and Lilly's own pharmacies (NovoCare and LillyDirect, from $149 a month) and TrumpRx are also chasing the cash-pay pie.
  • The valuation is stretched: after a gain of about 36% in June, the current $32.70 is above the sell-side consensus target of $28-29
  • A technical breakdown and regulatory worries caused the pullback on 25 Jun
  • The FDA peptide advisory meeting on 23-24 Jul is a binary event, and the downside risk has not gone away

Sources 7

  1. Reuters
  2. The Independent
  3. Business Group on Health survey
  4. Novo (Jamey Millar)
  5. DocShah / Raul Shah
  6. TipRanks
  7. Sell-side analyst consensus

A brief is a lead for our research, not a verified conclusion or advice.